Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, M.D., Ph.D., Dong-Wan Kim, M.D., Ph.D., Ranee Mehra, M.D., Daniel S.W. Tan, M.B., B.S., Enriqueta Felip, M.D., Ph.D., Laura Q.M. Chow, M.D., D. Ross Camidge, M.D., Ph.D., Johan Vansteenkiste, M.D., Ph.D., Sunil Sharma, M.D., Tommaso De Pas, M.D., Gregory J. Riely, M.D., Ph.D., Benjamin J. Solomon, M.B., B.S., Ph.D., Juergen Wolf, M.D., Ph.D., Michael Thomas, M.D., Martin Schuler, M.D., Geoffrey Liu, M.D., Armando Santoro, M.D., Yvonne Y. Lau, Ph.D., Meredith Goldwasser, Sc.D., Anthony L. Boral, M.D., Ph.D., and Jeffrey A. Engelman, M.D., Ph.D.

N Engl J Med 2014; 370:1189-1197March 27, 2014DOI: 10.1056/NEJMoa1311107

Comments open through April 2, 2014

Abstract

Article

References

Citing Articles (1)

Comments

CITING ARTICLES

1
Thomas , Roman K. , . (2014) Overcoming Drug Resistance in ALK-Rearranged Lung Cancer. New England Journal of Medicine 370:13, 1250-1251
Full Text